Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.

Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD

Diabetes & metabolic syndrome12 Feb 2022Cited by 116 (Europe PMC)

PMID35217468DOI10.1016/j.dsx.2022.102427PepBankPUB-35217468

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study30

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewSafety outcome
In patients with type 2 diabetes, the review found 46 case reports of adverse drug reactions with liraglutide.
In plain wordsIn people with type 2 diabetes, the review found 46 case reports of side effects linked to liraglutide.
Peptide
Liraglutide
Outcome
Not applicableAdverse drug reaction case reports with liraglutide
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Cases
46 n
liraglutide
Source sentences
Summary
The study identified 120 cases of GLP-1 agonists associated ADRs (liraglutide - 46, exenatide - 46, dulaglutide - 20, semaglutide - 4, albiglutide - 2, lixisenatide - 2).
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
Report a problemFND-3521746801
02HumanSystematic reviewSafety outcome
In patients with type 2 diabetes, the review found 4 case reports of adverse drug reactions with semaglutide.
In plain wordsIn people with type 2 diabetes, the review found 4 case reports of side effects linked to semaglutide.
Peptide
Semaglutide
Outcome
Not applicableAdverse drug reaction case reports with semaglutide
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Cases
4 n
semaglutide
Source sentences
Summary
The study identified 120 cases of GLP-1 agonists associated ADRs (liraglutide - 46, exenatide - 46, dulaglutide - 20, semaglutide - 4, albiglutide - 2, lixisenatide - 2).
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
Report a problemFND-3521746802

Studies that did not test the peptide alone28

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
The review found 120 case reports of adverse drug reactions across pooled GLP-1 agonists.
In plain wordsThe review found 120 case reports of side effects across GLP-1 drugs as a group.
Peptide
Liraglutide
Outcome
Not applicableTotal GLP-1 agonist adverse drug reaction cases
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Cases
120 n
all GLP-1 agonists
Source sentences
Summary
The study identified 120 cases of GLP-1 agonists associated ADRs (liraglutide - 46, exenatide - 46, dulaglutide - 20, semaglutide - 4, albiglutide - 2, lixisenatide - 2).
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746803
04HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
The review found 120 case reports of adverse drug reactions across pooled GLP-1 agonists.
In plain wordsThe review found 120 case reports of side effects across GLP-1 drugs as a group.
Peptide
Semaglutide
Outcome
Not applicableTotal GLP-1 agonist adverse drug reaction cases
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Cases
120 n
all GLP-1 agonists
Source sentences
Summary
The study identified 120 cases of GLP-1 agonists associated ADRs (liraglutide - 46, exenatide - 46, dulaglutide - 20, semaglutide - 4, albiglutide - 2, lixisenatide - 2).
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746804
05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, gastrointestinal disorders were the most common reported reaction (40 cases).
In plain wordsAcross GLP-1 drugs as a group, stomach and gut problems were the most often reported side effect, in 40 cases.
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Cases
40 n
gastrointestinal
Source sentences
Summary
gastrointestinal disorders (n = 40)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746805
06HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, gastrointestinal disorders were the most common reported reaction (40 cases).
In plain wordsAcross GLP-1 drugs as a group, stomach and gut problems were the most often reported side effect, in 40 cases.
Peptide
Semaglutide
Outcome
Not applicableGastrointestinal adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Cases
40 n
gastrointestinal
Source sentences
Summary
gastrointestinal disorders (n = 40)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746806
07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 23 case reports described renal adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 23 case reports described kidney side effects.
Peptide
Liraglutide
Outcome
Not applicableRenal adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Kidney and urinary
Measurements
Cases
23 n
renal
Source sentences
Summary
renal (n = 23)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746807
08HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 23 case reports described renal adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 23 case reports described kidney side effects.
Peptide
Semaglutide
Outcome
Not applicableRenal adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Kidney and urinary
Measurements
Cases
23 n
renal
Source sentences
Summary
renal (n = 23)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746808
09HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 14 case reports described dermatologic adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 14 case reports described skin side effects.
Peptide
Liraglutide
Outcome
Not applicableDermatologic adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Skin and wound
Measurements
Cases
14 n
dermatologic
Source sentences
Summary
dermatologic (n = 14)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746809
10HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 14 case reports described dermatologic adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 14 case reports described skin side effects.
Peptide
Semaglutide
Outcome
Not applicableDermatologic adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Skin and wound
Measurements
Cases
14 n
dermatologic
Source sentences
Summary
dermatologic (n = 14)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746810
11HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 10 case reports described hepatic adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 10 case reports described liver side effects.
Peptide
Liraglutide
Outcome
Not applicableHepatic adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Liver
Measurements
Cases
10 n
hepatic
Source sentences
Summary
hepatic (n = 10)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746811
12HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 10 case reports described hepatic adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 10 case reports described liver side effects.
Peptide
Semaglutide
Outcome
Not applicableHepatic adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Liver
Measurements
Cases
10 n
hepatic
Source sentences
Summary
hepatic (n = 10)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746812
13HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 13 case reports described immunologic adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 13 case reports described immune side effects.
Peptide
Liraglutide
Outcome
Not applicableImmunologic adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Immune and inflammation
Measurements
Cases
13 n
immunologic
Source sentences
Summary
immunologic (n = 13)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746813
14HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 13 case reports described immunologic adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 13 case reports described immune side effects.
Peptide
Semaglutide
Outcome
Not applicableImmunologic adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Immune and inflammation
Measurements
Cases
13 n
immunologic
Source sentences
Summary
immunologic (n = 13)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746814
15HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 7 case reports described endocrine or metabolic adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 7 case reports described hormone or metabolic side effects.
Peptide
Liraglutide
Outcome
Not applicableEndocrine/metabolic adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Measurements
Cases
7 n
endocrine/metabolic
Source sentences
Summary
endocrine/metabolic (n = 7)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746815
16HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 7 case reports described endocrine or metabolic adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 7 case reports described hormone or metabolic side effects.
Peptide
Semaglutide
Outcome
Not applicableEndocrine/metabolic adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Measurements
Cases
7 n
endocrine/metabolic
Source sentences
Summary
endocrine/metabolic (n = 7)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746816
17HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 3 case reports described hematologic adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 3 case reports described blood-related side effects.
Peptide
Liraglutide
Outcome
Not applicableHematologic adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Cases
3 n
hematologic
Source sentences
Summary
hematologic (n = 3)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746817
18HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 3 case reports described hematologic adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 3 case reports described blood-related side effects.
Peptide
Semaglutide
Outcome
Not applicableHematologic adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Cases
3 n
hematologic
Source sentences
Summary
hematologic (n = 3)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746818
19HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 3 case reports described angioedema.
In plain wordsAcross GLP-1 drugs as a group, 3 case reports described angioedema (swelling under the skin).
Peptide
Liraglutide
Outcome
Not applicableAngioedema, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Immune and inflammation
Measurements
Cases
3 n
angioedema
Source sentences
Summary
angioedema (n = 3)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746819
20HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 3 case reports described angioedema.
In plain wordsAcross GLP-1 drugs as a group, 3 case reports described angioedema (swelling under the skin).
Peptide
Semaglutide
Outcome
Not applicableAngioedema, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Immune and inflammation
Measurements
Cases
3 n
angioedema
Source sentences
Summary
angioedema (n = 3)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746820
21HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 2 case reports described neurologic adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 2 case reports described nervous system side effects.
Peptide
Liraglutide
Outcome
Not applicableNeurologic adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Measurements
Cases
2 n
neurologic
Source sentences
Summary
neurologic (n = 2)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746821
22HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 2 case reports described neurologic adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 2 case reports described nervous system side effects.
Peptide
Semaglutide
Outcome
Not applicableNeurologic adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Measurements
Cases
2 n
neurologic
Source sentences
Summary
neurologic (n = 2)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746822
23HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 2 case reports described cardiovascular adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 2 case reports described heart or blood vessel side effects.
Peptide
Liraglutide
Outcome
Not applicableCardiovascular adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Cardiovascular
Measurements
Cases
2 n
cardiovascular
Source sentences
Summary
cardiovascular (n = 2)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746823
24HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 2 case reports described cardiovascular adverse drug reactions.
In plain wordsAcross GLP-1 drugs as a group, 2 case reports described heart or blood vessel side effects.
Peptide
Semaglutide
Outcome
Not applicableCardiovascular adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Cardiovascular
Measurements
Cases
2 n
cardiovascular
Source sentences
Summary
cardiovascular (n = 2)
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746824
25HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 1 case report described a psychiatric adverse drug reaction.
In plain wordsAcross GLP-1 drugs as a group, 1 case report described a mental health side effect.
Peptide
Liraglutide
Outcome
Not applicablePsychiatric adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Mental health and mood
Measurements
Cases
1 n
psychiatric
Source sentences
Summary
1 from each of psychiatric, reproductive, generalized edema problems
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746825
26HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 1 case report described a psychiatric adverse drug reaction.
In plain wordsAcross GLP-1 drugs as a group, 1 case report described a mental health side effect.
Peptide
Semaglutide
Outcome
Not applicablePsychiatric adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Mental health and mood
Measurements
Cases
1 n
psychiatric
Source sentences
Summary
1 from each of psychiatric, reproductive, generalized edema problems
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746826
27HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 1 case report described a reproductive adverse drug reaction.
In plain wordsAcross GLP-1 drugs as a group, 1 case report described a reproductive side effect.
Peptide
Liraglutide
Outcome
Not applicableReproductive adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Reproductive and sexual health
Measurements
Cases
1 n
reproductive
Source sentences
Summary
1 from each of psychiatric, reproductive, generalized edema problems
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746827
28HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 1 case report described a reproductive adverse drug reaction.
In plain wordsAcross GLP-1 drugs as a group, 1 case report described a reproductive side effect.
Peptide
Semaglutide
Outcome
Not applicableReproductive adverse drug reactions, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Reproductive and sexual health
Measurements
Cases
1 n
reproductive
Source sentences
Summary
1 from each of psychiatric, reproductive, generalized edema problems
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746828
29HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 1 case report described generalized edema.
In plain wordsAcross GLP-1 drugs as a group, 1 case report described body-wide swelling.
Peptide
Liraglutide
Outcome
Not applicableGeneralized edema, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Cases
1 n
generalized edema
Source sentences
Summary
1 from each of psychiatric, reproductive, generalized edema problems
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3521746829
30HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
Across pooled GLP-1 agonists, 1 case report described generalized edema.
In plain wordsAcross GLP-1 drugs as a group, 1 case report described body-wide swelling.
Peptide
Semaglutide
Outcome
Not applicableGeneralized edema, pooled GLP-1 agonists
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Cases
1 n
generalized edema
Source sentences
Summary
1 from each of psychiatric, reproductive, generalized edema problems
1 context sentence(design, population, supporting numbers)
Summary · context
Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3521746830

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.

Summary

Results from this study30

Studies that did not test the peptide alone28

Version history

Subjects

Publication types

MeSH terms

Keywords